Progyny (PGNY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.55
- Estimate
- $0.53
- Surprise
- +4.6%
- Score at report (before → after)
- 5.9 → 6.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Progyny (PGNY) beat the $0.53 estimate with diluted EPS of $0.55 — a clear 4.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PGNY Hold at 6.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +4.6% surprise compares with a +13.7% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $25.94
- Price target
- $29.80
- Stop
- $24.50
- Upside to target
- +14.9%
- Reward-to-risk
- 2.7:1
The stock trades at 28.6× trailing but 11.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
PGNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Healthcare Plans
- Market cap
- $2.04B
- P/E (fwd)
- 11.5
- P/E (ttm)
- 28.6
- 52-week range
- $16.10–$33.06
- Off 52-week high
- 21.5%
- RSI (14)
- 56
- Volume vs avg
- 1.02×
- Score today
- 6.4/10